cbdMD, Inc. reported earnings results for the first quarter ended December 31, 2023. For the first quarter, the company reported sales was USD 5.38 million compared to USD 6.24 million a year ago. Revenue was USD 5.38 million compared to USD 6.09 million a year ago.
Net loss was USD 0.996501 million compared to USD 3.96 million a year ago. Basic loss per share from continuing operations was USD 0.67 compared to USD 3.7 a year ago. Diluted loss per share from continuing operations was USD 0.67 compared to USD 3.7 a year ago.
cbdMD, Inc. is a consumer wellness company focused on the development, manufacturing, marketing, and sale of supplement brands powered by natural compounds. Its hemp-derived cannabinoids, include full-spectrum cannabidiol (CBD) formulations, hemp-derived Delta-9 THC products and a range of functional products designed to address key wellness needs, such as sleep, recovery, mood, discomfort, mobility, cognitive function, and stress management. It operates a multi-brand portfolio anchored by its flagship cbdMD line, which offers oils, gummies, capsules, soft-gels, topicals, functional formulations, and hemp-derived compliant Delta-9 THC products. Its Paw CBD pet-wellness brand provides tinctures, chews, and topicals for dogs and cats. Its ATRX platform offers non-cannabinoid functional ingredients such as functional mushrooms. Its Herbal Oasis (Oasis) brand is a premium hemp-derived THC-infused social seltzer that blends cannabinoids and nootropic mushrooms.
